Lloyd Sems - Cyclacel Pharmaceuticals Independent Director

CYCC
 Stock
  

USD 0.84  0.01  1.20%   

  Director
Mr. Lloyd M. Sems serves as Independent Director of Cyclacel Pharmaceuticals, Inc. Mr. Sems has served as a director of the Company and on behalf of the holders of the Preferred Stock since May 2011. Mr. Sems currently serves as President of Sems Capital, LLC and Capital Edge, LLC, both of which he founded in October 2003. Previously, Mr. Sems served as Director of Research and Portfolio Manager for Watchpoint Asset Management. Mr. Sems served on the boards of EMAK Worldwide, Inc. from February 2010 to April 2010 and SportHaley Holdings from April 2009 to December 2012. He currently serves as a director of Determine, Inc., which he joined in June 2008
Age: 44  Director Since 2011      
908 517 7330  https://www.cyclacel.com
Sems holds a BS degree in Business Administration and Finance from Albright College.

Cyclacel Pharmaceuticals Management Efficiency

Cyclacel Pharmaceuticals has return on total asset (ROA) of (0.4167) % which means that it has lost $0.4167 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6014) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cyclacel Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cyclacel Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cyclacel Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cyclacel Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cyclacel to invest in growth at high rates of return. When we think about Cyclacel Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

DIRECTOR Since

Stacey MobleyHP Inc
2015
Carl BassHP Inc
2015
Chip BerghHP Inc
2015
Subra SureshHP Inc
2015
Stacy BrownPhilpotHP Inc
2015
Mary CitrinoHP Inc
2015
Shumeet BanerjiHP Inc
2011
Stephanie BurnsHP Inc
2015
Robert BennettHP Inc
2013
Aida AlvarezHP Inc
2016
Yoky MatsuokaHP Inc
2019
Rajiv GuptaHP Inc
2013
James SkinnerHP Inc
2013
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Cyclacel Pharmaceuticals (CYCC) is traded on NASDAQ Exchange in USA and employs 14 people. Cyclacel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Cyclacel Pharmaceuticals Leadership Team

Elected by the shareholders, the Cyclacel Pharmaceuticals' board of directors comprises two types of representatives: Cyclacel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gill Christie, Director HR
Samuel Barker, Director
Christopher Henney, Independent Vice Chairman of the Board
Gregory Hradsky, Independent Director
John Banham, Independent Director
Robert Westwood, Head Devel
Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director
Nicholas Bacopoulos, Independent Director
Lloyd Sems, Independent Director
David UPrichard, Independent Chairman of the Board
Judy Chiao, Vice President - Clinical Development and Regulatory Affairs
Mark MD, VP Officer
Robert Spiegel, Independent Director
Spiro Rombotis, CEO and President and Executive Director

Cyclacel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cyclacel Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cyclacel Pharmaceuticals' short interest history, or implied volatility extrapolated from Cyclacel Pharmaceuticals options trading.

Pair Trading with Cyclacel Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclacel Pharmaceuticals

-0.66RETAReata Pharmaceuticals Normal TradingPairCorr
-0.6JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.1 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.